Company news
Neuroscientific Biopharmaceuticals Ltd. (ASX:NSB) news
Every Neuroscientific Biopharmaceuticals Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
View Neuroscientific Biopharmaceuticals Ltd. stock analysis →
Press releases & updates
2026 Annual Report & Appendix 4E
August 25, 2026
Remarkable Results from Patients treated with StemSmart
May 25, 2026
Half Yearly Report and Accounts
February 25, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Successful Clinical Results Achieved under Special Access
January 12, 2026
Trading Halt
January 8, 2026
Fourth Patient Commences StemSmart MSC Treatment
November 10, 2025
2025 Annual Report & Appendix 4E
August 28, 2025
Previous StemSmart Studies Support Renal Transplantation
August 27, 2025
Experienced Cell Therapy Executive Appointed CEO
July 27, 2025
StemSmart Acquisition Complete
June 26, 2025
Previous StemSmart Studies Demonstrate Clinical Response
June 18, 2025
NeuroScientific to Acquire Leading Stem Cell Technology
April 15, 2025
2024 Annual Report & Appendix 4E
August 29, 2024
Appointment of Executive Director & FDA Pre-Ind Meeting
April 1, 2024
NSB Receives A$2.2M Research & Development Tax Refund
March 19, 2024
Resignation of CEO
December 1, 2023
Appointment of CEO
August 31, 2023
2023 Annual Report and Appendix 4E
August 25, 2023
Positive treatment effect in MS animal study
March 14, 2023
R&D Tax Incentive Refund Received
February 1, 2023
NSB files new patent
December 4, 2022
Appointment of Interim CEO
November 22, 2022
Investor Update Presentation
September 20, 2022
CEO Resignation
September 9, 2022
HREC decision to not approve Phase I Clinical Trial
September 6, 2022
2022 Annual Report and Appendix 4E
August 29, 2022
NeuroScientific releases FY2022 Results
August 29, 2022
HREC Submission for Phase I Clinical Trial
July 12, 2022
First Subject Recruited for Early-Phase Clinical Trial
June 30, 2022
Positive results in MS animal study
June 14, 2022
Ethics Approval Granted for Early-Phase Clinical Trial
June 7, 2022
HREC Submission for early-phase Clinical Trial
May 10, 2022
Positive safety result supports advance to clinical trials
April 13, 2022
New data demonstrates EmtinB activity in autoimmune diseases
March 10, 2022
NSB 1HY22 Key Activity Highlights
February 27, 2022
Successful completion of key studies in lead up to Phase I
February 7, 2022
Positive off-target safety assessment of EmtinB
December 23, 2021
Positive results in biomarker characterisation of Emtins
December 20, 2021
Completion of Safety Pharmacology Studies
October 17, 2021
NSB Receives R&D Advance & Overseas Finding
September 2, 2021
Positive Results in Multiple Sclerosis Study
August 30, 2021
2021 Annual Report and Appendix 4E
August 27, 2021
Results from Pulmonary Studies Clarification
August 20, 2021
Pause in Trading
August 19, 2021
Results from Pulmonary Studies
August 18, 2021
Quarterly Update and Appendix 4C
July 30, 2021
Successful completion of pivotal ocular safety study
July 1, 2021
NSB partners with Linear Research for Phase I Clinical Study
June 22, 2021
R&D Tax Rebate Received
May 31, 2021